Definium Therapeutics Phase 3 Results Lift Shares
Definium Therapeutics Phase 3 results show DT120 ODT met primary and secondaries with favorable tolerability, prompting a webcast and investor repricing.
KEY TAKEAWAYS
- Emerge met the primary endpoint with an 8.1-point placebo-adjusted MADRS benefit at Week 6 (p<0.0001).
- DT120 ODT 100 µg was generally well tolerated; 99% of treatment-emergent adverse events were mild or moderate.
- DFTX shares rose roughly 53% at 13:38 ET following the topline readout and a scheduled webcast.
HIGH POTENTIAL TRADES SENT DIRECTLY TO YOUR INBOX
Add your email to receive our free daily newsletter. No spam, unsubscribe anytime.
Definium Therapeutics, Inc. (NASDAQ: DFTX) reported Phase 3 results in a June 22, 2026, press release, stating the Emerge study met its primary and all key secondary endpoints. The company said it would hold an 8 a.m. EDT webcast to discuss the topline data.
Emerge Trial Results and Safety
The Emerge trial was a randomized, double-blind, placebo-controlled Phase 3 study that enrolled 149 adults aged 18 to 74 across 20 sites. It tested a single 100 µg dose of DT120 orally disintegrating tablet (DT120 ODT), described as lysergide (LSD), for major depressive disorder.
The primary endpoint measured change from baseline on the Montgomery–Åsberg Depression Rating Scale (MADRS) at Week 6. The active arm showed a −13.3 point change versus −5.2 for placebo, a placebo-adjusted improvement of 8.1 points (p<0.0001). All key secondary endpoints were met, including a Week 1 placebo-adjusted MADRS improvement of 14.2 points (p<0.0001) and a Week 12 improvement of 7.3 points (p<0.0001). Clinician-rated Clinical Global Impression–Severity (CGI-S) scores also favored the active treatment, indicating early onset and sustained benefit over three months.
DT120 ODT was generally well tolerated. The release reported that 99% of treatment-emergent adverse events were mild or moderate, with no serious adverse events or suicidality signals. The safety profile will be central to evaluating the clinical utility alongside efficacy.
Market Reaction and Webcast
Following the topline announcement, Definium Therapeutics shares rose roughly 53% at 13:38 ET on June 22. The market response reflected investor focus on the combination of early and sustained clinical improvement and the tolerability profile.
The company scheduled a live webcast to discuss the topline results, which will allow investors and analysts to examine the full dataset and assess durability, safety, and potential next steps for the program. This webcast represents the company’s primary public event following the data release and will shape near-term investor attention.
